Breckenridge Brewery Launches New Seasonal Brew: Spring Forward Grapefruit IPA

Sandoz to confirm strategic roadmap and highlight pipeline catalysts at 43rd Annual J.P. Morgan Healthcare Conference

Correction: GUERBET : Financial agenda for 2025

Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

Biomea Fusion to Become a Diabetes & Obesity Medicines Company

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care

Salarius Pharmaceuticals and Decoy Therapeutics Announce Definitive Merger Agreement

Jupiter Neurosciences Announces Strategic Focus on NLRP3 Pathway in Future JOTROL™ Trials

Kiniksa Pharmaceuticals Reports Preliminary 2024 Net Product Revenue and Provides 2025 Net Product Revenue Guidance

Arbutus Provides 2025 Corporate and Financial Update

Avacta Appoints Brian Hahn as Chief Financial Officer

George Medicines signs exclusive licensing agreement with Bausch Health to commercialize GMRx2 in Canada, Mexico, Columbia and Central America

Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2025 Outlook

Aquestive Therapeutics Provides Business Update and Outlines Key 2025 Objectives

Chimerix to Speak Today at The White House Cancer Moonshot Forum

Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference

Nurix Therapeutics Outlines 2025 Goals and Objectives for Advancement of Its Robust Pipeline in Cancer and Autoimmune Diseases

ANI Pharmaceuticals Provides Preliminary Fourth Quarter and 2024 Financial Results and Preliminary 2025 Outlook

Madrigal Pharmaceuticals Announces Preliminary* Fourth-Quarter and Full-Year 2024 Net Sales, Year-End Cash and Total Patients on Rezdiffra

Novartis Entresto® US patent upheld by US Court of Appeals

Idorsia to call for a bondholder meeting

Press Release: Sarclisa obtains first approval in China for the treatment of adult patients with relapsed or refractory multiple myeloma

Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference

Ascendis Pharma Provides Business and Strategic Roadmap Update at 43rd Annual J.P. Morgan Healthcare Conference

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Virbac : Declaration of the number of shares and voti

World Orphan Drug Alliance expands to Canada and full LATAM region, completing the first truly global commercialization offering

Recludix Pharma to Present at the Annual J.P. Morgan Healthcare Conference

Inozyme Pharma Announces Positive Interim Data for INZ-701 in Infants and Young Children with ENPP1 Deficiency and Key Program Updates

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

Tilray Brands Reports Q2 2025 Financial Results

iTeos Announces 2025 Strategic Priorities and Anticipated Milestones

AscellaHealth Releases Q4 2024 Specialty & Rare Pipeline Digest™ Featuring Key Specialty Drug, Biosimilar, Cell and Gene Therapy Approvals

Frontier Medicines Announces FMC-220, the First Covalent p53 Y220C Activator Development Candidate, with Best-in-Class Potential

Zentalis Pharmaceuticals Announces Azenosertib Fast Track Designation and Virtual Corporate Event to Present Updated Data from Azenosertib Clinical Studies

Press Release: New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Frontier Medicines to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Avadel Announces Preliminary 2024 Results and 2025 Commercial Priorities to Accelerate the LUMRYZ Launch

Cognition Therapeutics CEO Participating in Longwood and Sachs Conferences

Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Teva Pharmaceuticals

Rapafusyn Pharmaceuticals to Showcase Its Molecular Glue Drug Discovery Platform at WuXi Global Forum

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Collegium Provides 2025 Financial Guidance and Business Update

ViGeneron Announces FDA Rare Pediatric Disease Designation for VG901 and DSMB Approval to Advance Dose Escalation in Phase 1b Retinitis Pigmentosa Trial

Centessa Pharmaceuticals Announces Appointment of Stephen Kanes, MD PhD, as Chief Medical Officer

Atea Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference

iTeos to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Gary Ainsworth as Vice President of Market Access

Helsinn Group and ESTEVE sign a partnership agreement renewal to commercialize AKYNZEO® and ALOXI® in Germany

Roche purchases shares in tender offer for Poseida Therapeutics, Inc.

Cassava Sciences Provides a Business Update

Regeneron to Report Fourth Quarter and Full Year 2024 Financial and Operating Results and Host Conference Call and Webcast on February 4, 2025

Ipsen - Half year statement - 2024 12 31

Ipsen - December 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

Shuttle Pharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cyclarity Therapeutics Secures Approval for First-in-Human Clinical Trial

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Repligen Corporation to Present at 43rd Annual J.P. Morgan Healthcare Conference

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results